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Differential scanning calorimeterhas led to the introduction of three drugs — oseltamivir (GS-4104), zanamivir
(GG-167) and peramivir (RWJ-270201) which target the enzyme neuraminidase, for treatment of inﬂuenza
infections. Using comparative docking studies we propose that more potent molecules against neuramini-
dase can be obtained by appending extra positively charged substituents at the C5 position of the oseltamivir
skeleton. This provides an additional interaction with the enzyme and may overcome the problem of
resistance encountered with these drugs. To get an insight into the transport and absorption of oseltamivir —
the ethyl ester prodrug (GS-4104) as well as its mechanism of action, we have carried out 1H, 13C, 31P NMR,
DSC and TEM studies on GS-4104 with model membranes prepared from DMPC/DPPC/POPC. These studies
reveal that interactions between GS-4104 and the membrane are both electrostatic (involving H-bonding)
and hydrophobic (involving the hydrophobic chain and cyclohexene ring of GS-4104) in nature. The prodrug
is seen to increase the ﬂuidity as well as stabilize the bilayer phase of the membrane. This property may
be responsible for preventing viral entry into the cells by preventing fusion of the virus outer coat with the
cell membrane.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The danger of the highly pathogenic H5N1 inﬂuenza virus is not
only its high fatality but also its resistance to commercially available
drugs. The inﬂuenza virus contains two surface glycoproteins,
haemagglutinin (HA) and neuraminidase (NA) [1,2]. HA is responsible
for the binding of the virus to the target cells via the terminal sialic
acid residue in glycoconjugates. In contrast, NA catalyzes the removal
of the terminal sialic acid linked to glycoproteins and glycolipids. It has
been postulated that NA activity is necessary in the elution of newly
formed viruses from infected cells by digesting sialic acid in the HA
receptor [3,4]. Because of its essential role in inﬂuenza virus
replication, and its highly conserved active sites, inhibiting NA can
delay the release of progeny virus from the surface of infected cells,
thereby suppressing the viral population. NA has therefore become an
important target for drug design against inﬂuenza viruses.
Studies on DANA (2,3-didehydro-2-deoxy-N-acetylneuraminic
acid) [5], a prototype NA inhibitor, which is a sialic acid (endogenous
substrate) analogue has lead to drugs like oseltamivir— the ethyl ester
prodrug (GS-4104) [6], zanamivir (GG-167) [7] and peramivir (RWJ-
270201) [8] (Fig. S1). Zanamivir has poor bioavailability and isll rights reserved.therefore administered by inhalation. On the other hand, GS-4104 as
the phosphate (Fig. 1a) is the ﬁrst orally active neuraminidase
inhibitor approved for the treatment of both inﬂuenza A and B
infections [9].
GS-4104 [Ethyl-(3R, 4R, 5S)-(1-ethylpropyloxy)-4-acetamido-5-
amino-1-cyclohexene-1-carboxylate)] is an ethyl ester prodrug
which is hydrolyzed to the active form oseltamivir carboxylate (GS-
4071, Fig. 1b) [10]. GS-4071 has poor oral bioavailability (less than 5%
in rats) [11]; on the other hand, the prodrug GS-4104 is considerably
more hydrophobic (log P=0.36) than GS-4071 (log P=−2.1). This
increased lipophilicity is seen to improve the bioavailability of GS-
4071 which ranges from 30 to 60% in various animals species, after
oral administration of GS-4104 in its phosphate salt form [12]. The
transport of the drug and its absorption through the gastrointestinal
tract can be understood by studying the interaction of the prodrug GS-
4104 with model membranes prepared from a variety of phospholi-
pids. However, the antiviral activity ensues from the interaction of the
parent drug (GS-4071) with the neuraminidase receptor and this
aspect can be probed by docking studies of GS-4071 with its receptor.
The H5N1-NA active pocket (binding region) consists of 11
functional residues which participate in the catalytic reaction [13].
The binding region shows four well-conserved binding sites [14]. The
positively charged site-1 consists of Arg118, Arg292 and Arg371, which
interacts with the carboxylate group of the inhibitors. The negatively
charged site-2 consisting of Glu119, Glu227 and Asp151 interacts with
Fig. 1. Molecular structure of (a) oseltamivir phosphate — the ethyl ester prodrug (GS-4104) with atom labels (b) oseltamivir carboxylate (GS-4071).
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and Tyr178, which accommodates the acetyl group of the inhibitors
and site-4 consists of Glu276 and Glu277 which binds to the glycerol
part of sialic acid or the hydrophobic part of the inhibitors. Moreover,
presence of a 150 loop (residues 147–152), adjacent to the active site
leads to the formation of closed and open conformations, enabling
binding to the inhibitors [15].
In the present study we have used the approach of molecular
docking of GS-4071 to the enzyme H5N1-NA to explore the active site
and to provide clues to favorable binding interactions that can be used
to modify the existing drugs.
NA inhibitors inhibit the binding of HA and thus its ability to
promote attachment and fusion of the cell membrane to the virus
[16,17]. By this process it is likely to interfere with cell–cell fusion thus
interfering with the virus entry step. In view of this, we have carried
out a detailed investigation of GS-4104 (Fig. 1a) with model
membranes prepared fromDMPC/DPPC/POPC, using nuclearmagnetic
resonance (NMR) and differential scanning calorimetric (DSC)
techniques. The results have been further supported by transmission
electron microscopic (TEM) studies. These studies provide detailed
information on the effect of the drug on the lipid head group and the
conformation and dynamics of the hydrophobic chain [18,19].
The effect of GS-4104 on the phase of the bilayer membrane and its
mobility/ﬂuidity may have an implication on membrane fusion and
the viral replicative process as indicated in these studies. This
knowledge will be used in the future to design some new inhibitors
with better activity and hopefully lower viral resistance.
2. Experimental
2.1. Materials
Oseltamivir phosphate (GS-4104) was a gift from Cipla Ltd.,
India. 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were purchased
from Sigma Chemicals Co., USA; 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) from Avanti Polar Lipids Inc., Alabaster, AL,
USA. All chemicals were used without further puriﬁcation.
2.2. Sample preparation for NMR and DSC
Multilamellar vesicles were prepared using the standard proce-
dure [20]. First the desired quantity of DMPC or DPPC or POPC was
dissolved in chloroform. The solvent was evaporated with a stream of
nitrogen so as to deposit a lipid ﬁlm on the walls of the container. The
last traces of solvent were removed by vacuum drying for at least 1 h.The ﬁlm was hydrated with the required amount of a solution of GS-
4104 in D2O (pH 7.2) followed by incubation in a water bath at 50 °C
with repeated vortexing. The lipid concentrations were maintained at
100 mM for NMR and 50 mM for DSC experiments. The GS-4104
concentrations were varied from 1 mM to 100 mM for NMR and
0.5 mM to 50 mM for DSC studies. Unilamellar vesicles were prepared
by sonicating the above dispersions with a Branson sonicator-450 at
50% duty cycles, till optical clarity was obtained.
GS-4104 is reported to be stable at the temperature and pH used in
our experiments [10]. Further assurance of the stability comes from
the NMR spectra that have been recorded, which indicate that the
molecule is indeed stable and does not degrade under the experi-
mental conditions.
2.3. DSC experiments
DSC measurements were performed using the differential scan-
ning calorimeter VP-DSC (MicroCal, Northampton, MA, USA). The
samples were degassed under vacuum before being loaded into the
reference and sample cells. A scan rate of 10 °C/h was employed. Data
were analyzed with the software ORIGIN provided by MicroCal. All
experiments were carried out in the temperature range 20 °C to 60 °C.
Repeated scans for the same sample were generally superimposable.
2.4. NMR experiments
NMR experiments were recorded on a BRUKER AVANCE 500 MHz
spectrometer. 2D COSY, NOESY and ROESY [21–23] experiments were
recorded at 300 K. 31P and 13C NMR experiments were carried out
using a relaxation delay of 1 s and with broadband proton decoupling.
The NMR data was processed using Topspin 2.1.
2.5. TEM experiments
TEM experiments were performed on a Carl Zeiss Libra 120 EF TEM
(Germany) with LaB6 emitter and 120 kV accelerating voltage. Lipid
samples were deposited on Formvar®-carbon coated copper grids
(FCF400-Cu, Electron Microscopy Sciences, Hatﬁeld, PA) and allowed
to equilibrate. Excess liquid was removed with a ﬁlter paper and the
grid was air-dried.
2.6. Computational studies
Computational studies were carried out with the modeling
package Discovery Studio 2.0 (Accelrys Inc., USA) [24] running on a
Red Hat Enterprise Linux WS Workstation. Docking studies were
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Hat Enterprise Linux WS Workstation.
2.6.1. Preparation of enzyme and ligand for docking
The crystal structure of the enzyme H5N1-NA in complex with GS-
4071 was taken from the protein data bank (PDB code No. 2HU4,
H252Y mutant) [15]. The enzyme is an octamer of 8 chains; however
for docking studies only the monomeric unit was used. The mutated
residue (H252Y) was changed from tyrosine to histidine. All the water
molecules were deleted and hydrogens were added at pH 7. The
system was reﬁned using the CHARMm forceﬁeld with the backbone
atoms tethered by a force constant of 10 kcal/mol/Å, to a gradient of
0.1 kcal/mol/Å.
The structure of GS-4071 was energy minimized using the “Smart
Minimizer” method in DS2.0 that performs steepest descents and
conjugate gradients with the CHARMm force ﬁeld to a gradient of
0.01 kcal/mol/Å.
2.6.2. Docking studies
The following parameters in GOLD were permitted to change
during the docking runs: (a) the dihedral angles of the inhibitors (b)
the inhibitors' ring geometries (ﬂipping ring corners) (c) the dihedral
angles of enzyme OH and NH2 groups and (d) mappings of the H-
bonds between the inhibitor and enzyme. At the start of a docking run,
all these variables were randomized. Docking was carried out for 20
genetic algorithm (GA) runs, which was found sufﬁcient to reproduce
the binding pose of GS-4071 in 2HU4. Most of the other GA
parameters like population size and the genetic operators were left
at their default values. The binding sitewas deﬁned as a sphere of 10 Å
radius around the inhibitor. The docking protocol was validated by the
reproduction of the binding pose of GS-4071 in 2HU4. This protocol
was then used to dock the other inhibitors to H5N1, to determine their
preferred binding orientations. The docked poses were scored usingFig. 2. The most favored pose of oseltamivir carboxylate (GS-4071) in the H5N1-NA active sitGoldScore. Hydrogen bonds for all the inhibitors with the amino acid
residues of the active site were analyzed. The GOLD ﬁtness function is
made up of four components: protein-ligand hydrogen bond energy,
protein-ligand van der Waals energy (external vdw), ligand internal
vdw energy and ligand torsional strain energy. Poses were segregated
on the basis of GoldScore.
3. Results and discussion
3.1. Docking
Computational docking is one of the useful methods to investigate
molecular interactions. The inhibitors GS-4071, GG-167 and RWJ-
270201, DANA, and the endogenous substrate sialic acid were docked
into H5N1-NA. The poses of GS-4071 obtained by docking are depicted
in Fig. 2 and for the other inhibitors in Fig. 3. The hydrogen bonds
formed between the substrate/inhibitors and the enzyme are
summarized in Table 1.
It is observed from Table 1 that the number of hydrogen bonds in
the case of GS-4071 is smaller compared to the two contemporary
drugs GG-167 and RWJ-270201. For GS-4071, the interactions are
between the carboxylate group and Arg292, Arg371 and Tyr347; the
CfO of the carboxamide group of the drug with Arg152 and the NH2
group of the drug with Glu119 and Asp151. In case of GG-167, the
additional interactions are the guanidino amino group of the drug
with Trp178 and Glu227, and the glycerol hydroxyl group of the drug
with Glu276. These results indicate that the additional interactions in
case of GG-167 provided by the guanidino and glycerol moieties,
probably contribute to its lower resistance to NA seen among the
currently available drugs. RWJ-270201 also displays H-bond interac-
tions similar to GG-167.
Docking of sialic acid the endogenous substrate shows a binding
pattern very similar to the inhibitor GS-4071, except that it does note as seen by docking studies. H-bonds between the drug and the enzyme are indicated.
Fig. 3. Favored docking poses of ligands in the H5N1-NA active site. (a) Sialic acid (blue) and DANA (yellow) (b) zanamivir (GG-167, orange) and peramivir (RWJ-270201, pink).
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bonding interactions compared to the other inhibitors. This is also
supported by the lack of binding at Asp151 in our docking studies,
which probably explains the observed lower activity of DANA
compared to the other NA inhibitors [5]. The results correlate withthe fact that the lack of a positive charge on sialic acid and DANA
(presence of the hydroxyl group instead of an amino/guanidine group)
does not facilitate the interaction with Asp151 in these two cases.
Molecular modeling studies reveal that in order to accommodate
the hydrophobic side chain of GS-4071 in the active site, the
Table 1
Results of docking studies of oseltamivir (GS-4071) with H5N1-NA
Amino acid residues
of H5N1-NA
Oseltamivir
GS-4071
Zanamivir
GG-167
Ligands peramivir
RWJ-270201
DANA Sialic acid
ARG118 HO–CfO....HN HO–CfO....HN HO–CfO....HN
GLU119 NH2....OfC C–OH....OfC
ASP151 NH2....OfC NH2....OfC NH2....OfC
ARG152 HN–CfO....HN HN–CfO....HN HN–CfO....HN HN–CfO....HN HN–CfO....HN
TRP178 NH2....OfC
GLU227 NH2....OfC NH2....OfC
GLU276 C–OH....OfC
C–OH....OfC
ARG292 HO–CfO....HN HO–CfO....HN HO–CfO....HN HO–CfO....HN HO–CfO....HN
HO–CfO....HN HO–CfO....HN HO–CfO....HN
TYR347 HO–CfO....HO OfC–OH....HO HO....HO HO–CfO....HO
ARG371 OfC–OH....HN OfC–OH....HN OfC–OH....HN OfC–OH....HN OfC–OH....HN
HO–CfO....HN HO–CfO....HN HO–CfO....HN HO–CfO....HN HO–CfO....HN
H bonds 8 11 8 6 7
Atoms involved in hydrogen bonding from ligands (row) to amino acid residues of H5N1-NA (column) are underlined. Last row shows number of hydrogen bonds observed in case of
each ligands.
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binding pocket [26]. Analysis at the molecular level shows that the
amino acid Glu276 must rotate and bond with Arg224 to form such a
pocket. Further, the mutations R292K, N294S and H274Y prevent the
formation of the Glu276:Arg224 ionic interaction and therefore in
such mutants the rotation of Glu276 is inhibited. Consequently the
formation of the additional binding pocket is hindered, thereby
conferring resistance to GS-4071 [26]. The mutations nonetheless
allow the binding of the natural sialic acid substrate, so that the
mutated virus can survive and propagate. In contrast, the binding of
GG-167 to this pocket does not require any reorientation of amino
acids, so these mutated viruses remain sensitive to this drug [26].Fig. 4.DSC plots of DPPC (50mM)with different GS-4104 (as the phosphate salt) to lipid mola
as the free base i.e. without the phosphate group). The arrows indicate the position of the sOur studies on GG-167 are consistent with the above observations
along with an observed additional interaction of its guanidino group
with Trp178, Glu227 and Asp151 (Asp151 is part of site 2). At the same
time, GS-4071 does not show any interactionwith Trp178, Glu227 and
Glu276. This indicates that increasing molecular volume of GS-4071,
especially around the site-2, may help inmore precise binding thereby
decreasing the resistance of the enzyme towards the inhibitors.
In view of the above, and based on the docking results for GS-4071
and other inhibitors, we reason that modifying the molecular volume
of GS-4071 by extending the length of the C5-amino group, while
simultaneously increasing lipophilicity may strengthen the binding
interactions and overcome the problem of drug resistance.r ratios (a) 0:100 b) 1:100 c) 1:10 d) 1:5 e) 1:2 f) 1:1 and inset ﬁgure 1:1 (GS-4104 here is
houlder peaks (Tm1) due to the new phase.
Table 2
DSC studies showing the pretransition andmain transition temperatures values of DPPC
(50 mM) with varying oseltamivir molar ratios
Oseltamivir:DPPC Pretransition Main transition (Tm)
0:100 33.74 41.34
1:100 32.40 41.0
1:10 30.96 40.47
1:5 29.88 40.38
1:2 Broad 38.68
1:1 Broad 37.54
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The thermotropic aspect of drug–lipid interactions can be studied
with differential scanning calorimetry (DSC) by examining the
changes in the melting point (Tm) and the shape of the DSC trace
[27]. During heating, the lipid initially undergoes a pretransition
(Lβ′→Pβ′) from an ordered ‘gel’ state where the lipids are ordered and
tilted (Lβ′) to the Pβ′ state where the lipids are still ordered and in a gel
state but with a minimal tilt. The pretransition occurs before the main
transition and is small compared to the main one. During the main
transition (Pβ′→Lα) lipids undergo a change from the ordered state
(Pβ′) to a ‘ﬂuid’ disordered state Lα [28,29]. Fig. 4 shows the DSC curves
of DPPC incorporated with varying concentrations of GS-4104. It is
observed that the multilamellar structure of plain DPPC shows a
pretransition or low enthalpy transition at 33.7 °C (Fig. 4), which is an
indication of themobility of the choline part of the polar head of DPPC.
The mobility of the alkyl chain is seen in the main transition at 41.3 °C.
The effect of incorporation of GS-4104 at different concentrations
(from 0.5 mM to 50 mM) into DPPC bilayers is shown in Fig. 4b–f. The
addition of GS-4104 causes signiﬁcant changes in the pretransition as
well as in the main phase transition temperature (Tm) of the DPPC
bilayers (Table 2). Both the transition temperatures shift to a lowerFig. 5. 500 MHz 1H NMR spectrum of oseltamivir phosphate (GS-4104) in D2O at 300 K with
carbon atoms (Fig. 1).value and the peaks broaden with increasing concentration of the
drug. At a drug concentration of as low as 1:100 (drug:lipid molar
ratio), the pretransition peak shifts to a lower temperature (32.4 °C)
and the main transition peak shifts to 41.0 °C with a symmetrical
signal. At higher 1:10 and 1:5 molar ratios the pretransition shifts to
30.9 °C and 29.8 °C respectively, and the main transition peak shifts to
40.4 °C and 40.3 °C respectively. In addition, a shoulder appears at the
main transition (Tm1) at 41.3 °C and 41.2 °C respectively. At 1:2 molar
ratio, the pretransition peak is completely abolished and the main
transition shifts to a low of 38.6 °C with a prominent shoulder at
41.1 °C (Fig. 4e). At 1:1 molar ratio, where 50 mM GS-4104 was
incorporated into the lipid, a much more pronounced effect is
observed. The pretransition peak is completely abolished (broadened
nearly to the baseline), the main transition peak shifts to a still lower
value (37.5 °C) and the shoulder peak is distinctly converted to an
inseparable prominent peak (Fig. 4f). Moreover, the intensity of the
new peak corresponding to a new phase increases with increasing
drug concentration. The Tm and Tm1 transitions are observed probably
due to the coexistence of GS-4104-rich and GS-4104-poor DPPC
domains (phases) within the bilayer.
The presence of coexisting phases indicates phase segregation
which may arise from the effect of osmotic stress on DPPC bilayers
due to the presence of the phosphate group in GS-4104 [30]. This is
supported by studies carried out on modiﬁed GS-4104 where the
phosphate group has been removed, at 1:1 drug:lipid molar ratio. It
is observed that in this case the pretransition peak is abolished, the
main transition is broadened and shifted to 38.8 °C. However the
shoulder peak which was seen as indicated above (indicative of
phase segregation) is absent (Inset Fig. 4) at all concentrations
(ﬁgure not shown). This indicates that the phosphate group of the
GS-4104 is the one interacting with the polar head of the lipid
bilayer. In general, the pretransition peak is very sensitive to the
presence of impurities and is abolished even at small quantities of
impurities [31]. In the present case, however, the pretransition peakthe resonance assignments. The numbers in the brackets refer to the numbering of the
Table 3
1H-NMR chemical shift δ (ppm) of oseltamivir in D2O
Atoms δ (ppm)
C(2)H 6.76(s)
C(3)H 4.25(d)
C(8)H2 4.17(q)
C(4)H 3.97(q)
C(10)H 3.51(m)
C(5)H 3.46(m)
C(6)Ha 2.88(q)
C(6)Hb 2.45(m)
C(16)H3 2.0(s)
C(11)H2 1.5(m)
C(13)H2 1.48(m)
C(9)H3 1.20(t)
C(12)H3 0.80(t)
C(14)H3 0.76(t)
In parenthesis are the multiplicities of the peaks (s)—singlet, (d)—doublet, (t)—triplet,
(q)—quadruplet, (m)—multiplet.
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drug penetrates the lipid bilayer causing the pretransition to shift to
a lower temperature. This further suggests that the drug interacts
with the head group in such a manner that it stabilizes the
membrane architecture to a large extent. Secondly, a decrease in
the main transition temperature (∼3.8 °C) indicates that the drug
imparts a degree of ﬂuidity to the bilayer in order to position itself in
the hydrophobic core as well. These observations are further
supported by a recent DSC study where both cholesterol and peptide
were shown to reduce the Tm markedly and stabilize the ﬂuid phase
of the membranes [32].Fig. 6. 2D 1H NOSEY spectrum of DMPC unilamellar vesicles incorporated with oseltamivir ph
with a mixing time of 250 ms.3.3. NMR
The atoms labels for oseltamivir (GS-4104) as the phosphate salt
(Fig. 1a) relate to the 1H and 13C NMR resonances. The 1H NMR
spectrum of GS-4104 in D2O (Fig. 5) has been assigned using the 2D
COSY [21] spectrum (Fig. S2) and the chemical shifts are given in
Table 3. Comparison of the 1H NMR spectra of DMPC unilamellar
vesicles, GS-4104 in D2O and GS-4104 incorporated into DMPC
vesicles indicates no signiﬁcant changes in the chemical shift of DMPC
resonances on incorporation of GS-4104. However, the signals of GS-
4104 are broadened to a very large extent on incorporation into DMPC
vesicles (Fig. S3), indicating that GS-4104 gets immobilized in the lipid
bilayer due to various types of intermolecular interactions. Fig. 6
shows the 2D NOESY [22] spectrum of GS-4104 incorporated into
DMPC unilamellar vesicles. Such a spectrum can provide information
on intermolecular interactions from the intermolecular NOEs between
two molecules. These NOEs arise when the two atoms (within the
molecule or from two different molecules) are at a distance ≤5 Å apart.
The GS-4104 resonance assignments are indicated in the ﬁgure along
the F2 dimension. Intermolecular NOEs between the lipid and GS-
4104 are indicated in the F1 dimension. These are as follows: C(2)H of
GS-4104 with the C(β)H2 of the lipid head group; C(8)H2 of GS-4104
with C(β)H of the glycerol backbone and the N+(CH3)3 moiety in the
head group; C(6)H and C(10)H of GS-4104 with the (CH2)n chain of the
lipid; C(12,14)H3 and C(11,13)H2 of GS-4104 with the (CH2)n and the
CH3 groups of the lipid. Other peaks could not be unambiguously
assigned due to spectral overlap. Observation of these intermolecular
NOEs indicates that GS-4104 uses its hydrophobic chain and the
cyclohexene group to bind via hydrophobic interactions with the lipid
spanning both the head group as well as interior of the lipid bilayer.osphate (GS-4104) (1:5 drug:lipid molar ratio). The experiment was carried out at 303 K
Fig. 7.125.7 MHz 13C NMR spectra at 303 K. (a) DMPC (50mM) unilamellar vesicles, (b) oseltamivir phosphate (GS-4104,10 mM) and (c) DMPC unilamellar vesicles incorporated with
oseltamivir phosphate (GS-4104) (1:5 drug:lipid molar ratio). In (b) the asterisk (⁎) indicates signals of GS-4104 which are broad and beyond detection and dotted lines indicate shift
in GS-4104 signals on incorporation into DMPC vesicles.
Table 4
13C chemical shifts δ (ppm) of Oseltamivir phosphate in D2O and in DMPC vesicles (1:5
molar ratio) at 303 K
Atoms δ (ppm) In Lipid vesicles δ (ppm) Δδ (ppm)
C1 127.82 Broad beyond detection
C2 139.09 Broad beyond detection
C3 75.24 Broad beyond detection
C4 52.87 Broad beyond detection
C5 49.33 49.5 (broad) 0.17
C6 28.33 27.53 (broad) 0.8
C7 175.45 Broad beyond detection
C8 62.62 62.30 (broad) 0.32
C9 13.50 13.59 (broad) 0.09
C10 84.33 84.01 0.32
C11 25.69 25.80 (broad) 0.11
C12 8.64 8.71 0.07
C13 25.31 25.39 (broad) 0.08
C14 8.74 8.84 0.10
C15 167.62 Broad beyond detection
C16 22.60 Broad beyond detection
Δδ (ppm) indicates the difference in the chemical shift from drug in D2O to drug in
DMPC vesicles.
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could come from looking at 13C NMR spectra of GS-4104 incorporated
into the lipid bilayer (Fig. 7). While the 13C NMR spectrum of DMPC
was assigned from the literature [33], GS-4104 peaks were assigned
from the DEPT spectrum [34] as well as from the multiplicity pattern
of the resonances. The 13C chemical shifts of GS-4104 in D2O and in
lipid bilayers are listed in Table 4. The 13C spectra for unilamellar
DMPC vesicles as well as GS-4104 in D2O are characterized by sharp
lines (Fig. 7a and b). On incorporation of GS-4104 into DMPC
unilamellar vesicles, the lipid signals continue to remain sharp
while the GS-4104 signals show differential broadening. These can
be put into three categories: signals that remain sharp but are shifted;
those that are broad and shifted, and ﬁnally those that are broad
beyond detection (Table 4). This differential broadening of the GS-
4104 resonances arises because different parts of drug bind to the lipid
bilayer with differing afﬁnities.
Due to the broadening of signals it was difﬁcult tomeasure the spin
lattice relaxation time (T1) and spin–spin relaxation time (T2), which
are measures of the overall tumbling and segmental motions in the
molecule. In the fast tumbling range, both T1 and T2 are large, of the
order of few seconds [35]. The estimates of spin–spin relaxation times
(T2) from the line widths indicate that T2 values are of the order of
100 ms. The lower values of T2 indicate that GS-4104 losses its
mobility and becomes strongly bound to lipid bilayers resulting in a
freezing of its different motions. These results along with the NOEs
discussed above indicate that both hydrophilic as well as hydrophobic
interactions involve the cyclohexene ring and the hydrophobic chain
of GS-4104 with the lipid bilayers.
Membrane fusion is a ubiquitous process in biological systems and
involves the union of two opposing bilayers in order to complete
processes such as exocytosis or viral infection. A local departure from
the bilayer structure must take place in order to allow two lipid
membranes to merge into one. Agents known to induce the formation
of non-bilayer structures also promote membrane fusion [36–38].
Viral induced cell–cell fusion is known to be inhibited by cyclosporin
A, an agent that stabilizes the bilayer phase of membranes [39,40].
The 31P NMR resonance line shape is determined by the chemical
shift anisotropy (CSA) of the phosphate group coupled with the
molecularmotions near the head groups [41]. The shape of the 31P line
is used to detect polymorphism in model membranes [42]. In a
randomly oriented sample such as DMPC dispersions in the gel phase,the overall rotational rate is slow. One observes a sharp signal at
−20 ppm from lipid molecules with their long axis oriented
perpendicular to the direction of the magnetic ﬁeld, while for the
parallel alignment of the lipid molecules a broad shoulder appears at
25 ppm (Fig. 8a). A relatively small but sharp peak is observed at
0 ppm due to the formation of a small amount of unilamellar vesicles
with a small size that permits fast internal and tumbling motions. The
effect of GS-4104 on the 31P NMR line shape of DMPC vesicles was
studied as a function of drug concentration (Fig. 8b–d) as well as
temperature (Fig. S4). The build up of a sharp peak at zero ppm with
increasing GS-4104 concentration is due to the PO4− group associated
with the drug. The chemical shift anisotropy (CSA) can be measured
from the low and high ﬁeld (the σII and σ⊥ components) shoulders of
the spectrum. It is seen that with increasing concentration of GS-4104
(1:10 to 1:1 drug:lipid molar ratio) as well with varying temperature,
the drug causes a broadening of the low ﬁeld line (σII component of
the signal). Because of the broad line width of the low ﬁeld
component, the error in the measurement of the CSA is large (Fig. 8,
Fig. S4). However, there is a noticeable change (narrowing) in the CSA
parameter with increasing temperature (Fig. S4) of the perpendicular
Fig. 8. 202.4 MHz 31P NMR spectra of DMPC (100 mM) incorporated with different
concentrations of oseltamivir phosphate (GS-4104) at 303 K. Drug:lipid molar ratios are
a) 0:100, b) 1:5, c) 1:2 and d) 1:1.
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be attributed to motionally averaged isotropic phase above the phase
transition temperature. However, the characteristic features of the
bilayer (presence of both parallel and perpendicular components)
remain unchanged. This indicates that GS-4104 stabilizes the lipid
bilayer phase of DMPC [43,44].
Similar concentration and temperature dependence experiments
have been carried out with POPC vesicles as well. Fig. 9 shows the 31PFig. 9. 202.4 MHz 31P NMR spectra as a function of temperature (a) POPCmultilamellar vesicle
a 1:5 drug:lipid molar ratio. Inset ﬁgure shows the change in CSA (Hz) represented by Δσ=NMR spectra of POPC alone andwith GS-4104 at a 1:2 drug:lipidmolar
ratio as a function of temperature. In this case it is observed that there
is a partial averaging of the σ⊥ and σII components resulting in a
reduction in the CSAwhich is represented byΔσ=σ⊥−σII (inset Fig. 9).
The amount by which the CSA is reduced is related to the allowed
amplitude of themotion. At lower temperatures (283 K and 288 K) the
presence of GS-4104 causes hardly any change in the CSA. However,
the reduction in CSA increases with increasing temperature and a
maximum decrease in CSA caused by GS-4104 at 308 K is about
1780 Hz as compared to 765 Hz in case of pure POPC. Concentration
dependence experiments (carried out at 1:10 and 1:1 drug:lipid ratio)
do not show any noticeable change in CSA or line width of the signal
(ﬁgure not shown).
Studies have shown that stabilization of themembrane by antiviral
drugs can play an important role in inhibiting membrane fusion and
also antiviral activity [40]. Based on the above observations GS-4104 is
likely to be involved in preventing membrane fusion in addition to
inhibiting the NA activity.
In order to understand the role of the amide NH and amino NH2
groups of GS-4104 in interaction with the lipid membrane we have
recorded 1H NMR spectra of GS-4104 alone in CDCl3 (in order to avoid
NH exchange with D2O) and titrated with different lipid (DPPC)
concentrations (Fig. S5). It is observed that with increasing concentra-
tion of lipid, both NH and C5-NH2 peaks of GS-4104 shift downﬁeld.
There is no change in the chemical shift of other resonances. This
indicates that probably the NH2 and NH groups are involved in some
sort of hydrogenbondingwith the polar head group of the lipid bilayer.
3.4. TEM
TEM has evolved as an important tool to gain new information on
the form and structure of liposomes, as well as on the morphologicals (b) POPCmultilamellar vesicles incorporatedwith oseltamivir phosphate (GS-4104) at
σ⊥−σII, with temperature.
Fig. 10. Transmission electron microscope (TEM) picture of (a) DPPC multilamellar
vesicles and (b) vesicles incorporated with oseltamivir in 1:5 drug:lipid ratio.
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and other polyelectrolytes [45]. As discussed in the Introduction
section, NA inhibitors are known to inhibit the binding of HA to its
receptor, and thus its ability to promote attachment and fusion of cell
membrane to the virus [16,17]. The drug is therefore likely to interfere
with cell–cell fusion; through stabilization of the bilayer structure it
interferes with the virus entry step. In order to support the
stabilization of the lipid bilayer phase by GS-4104 as seen by NMR,
we have studied the phase behavior and the aggregate structure of
liposomes using TEM. Fig. 10 shows electron micrographs of DPPC
dispersions alone and in presence of GS-4104 (1:5 drug:lipid molar
ratio). It is observed that pure DPPC dispersions show the character-
istic bilayer features of large vesicles (Fig. 10a). On addition of GS-4104
the bilayer characteristics of the lipid dispersions is largely retained
and no polymorphism is observed. Moreover, there is a complete
absence of any fusion bodies in the micrograph (Fig. 10b). This is in
contrast to the studies with the fusogenic drug piroxicam which is
seen in TEM micrographs to induce membrane fusion [46] when
compared to control samples of DMPC dispersions.
These results thus indicate that GS-4104 binds to the cell
membrane in such a way that it stabilizes the bilayer character of
the membrane and thus prevents the cell–cell fusion which is an
important phenomenon during the viral entry in the host cell [47–49].
4. Conclusions
Oseltamivir—the ethyl ester prodrug (GS-4104) ﬂuidizes the
membrane and binds to both the hydrophilic head group (probably
involving the amino NH2 group) and the hydrophobic interior. This
may explain the facile transport of the hydrophobic prodrug through
the lipid membrane, resulting in its higher absorption from the gut. It
also seen to stabilize the bilayer character of the membrane; by which
mechanism it prevents membrane fusion of the virus with the cells.
Docking studies of oseltamivir (GS-4071) and marketed NA inhibitors
with H5N1 indicate the importance of molecular volume at site 2 of
the receptor. Therefore, increasing the chain length and lipophilicity
may strengthen the binding interactions and overcome the problem of
drug resistance. In order to enhance the molecular volume and
lipophilicity, introduction of functional groups with proper shape, size
and electronic charge are required. This will promote a snug ﬁt to the
receptor site and enhance its anti-viral effect. Efforts are on to suitably
modify oseltamivir based on these results, with the hope that these
modiﬁed structures may be able to overcome the problem of the
resistance of the mutated enzyme neuraminidase.
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